Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
» CRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CRTX Guru Trades in Q2 2013

Jim Simons 310,529 sh (+19.97%)
» More
Q3 2013

CRTX Guru Trades in Q3 2013

Mario Gabelli 20,400 sh (New)
Jim Simons 311,629 sh (+0.35%)
» More
Q4 2013

CRTX Guru Trades in Q4 2013

Jim Simons 380,774 sh (+22.19%)
Mario Gabelli 20,400 sh (unchged)
» More
Q1 2014

CRTX Guru Trades in Q1 2014

Mario Gabelli Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-03-31 Sold Out $9.48 - $9.65 $ 9.49-1%0
Mario Gabelli 2013-09-30 New Buy$7.99 - $9.81 $ 9.495%20400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DUJ1.Germany
Cornerstone Therapeutics, Inc., a Delaware Corporation founded in 2000. The Company is a specialty pharmaceutical company which commercializes products for the hospital and adjacent specialty markets. Its currently marketed and approved products include: CARDENE I.V., an FDA-approved premixed injection indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable; CUROSURF, an FDA-approved natural lung surfactant indicated for the treatment of Respiratory Distress Syndrome, or RDS, in premature infants; ZYFLO, the only FDA-approved leukotriene synthesis inhibitor indicated for prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older; BETHKIS, an inhaled tobramycin-based product indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa, or PA, approved by the FDA in October 2012; Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Suspension, or HP/CP ER Suspension, an FDA approved antitussive/antihistamine combination product that is a generic equivalent for the product currently sold under the Tussionex Pennkinetic,or Tussionex, brand name in the United States. Its customers consist of drug wholesalers, retail drug stores, mass merchandisers and grocery store pharmacies in the United States. It primarily sell products directly to drug wholesalers, which in turn distribute the products to retail drug stores, hospitals, mass merchandisers and grocery store pharmacies. It currently outsources the manufacturing of all of its commercially available products and the formulation development of its product candidates for use in clinical trials to third parties. It have U.S. and/or foreign trademark registrations and filings for certain of its corporate names, products (including CARDENE I.V., ZYFLO CR and ZYFLO) and product candidates (including RETAVASE and LIXAR). CUROSURF and BETHKIS are owned by Chiesi and are licensed to it for sales and marketing purposes in the United States. The Company faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions. The Company, its contract manufacturers and packagers, and its products and product candidates are subject to the Controlled Substances Act and DEA regulations thereunder.
» More Articles for CRTX

Headlines

Articles On GuruFocus.com
Cornerstone Therapeutics Is Selling Itself Too Cheap Oct 08 2013 
Weekly CEO Sells Highlight: Cornerstone Thr, Nvidia Corp, Interpublic Group, and Coffee Holding Co. Apr 08 2012 
Critical Therapeutics Inc. Reports Operating Results (10-K) Mar 03 2011 
Critical Therapeutics Inc. (CRTX) CFO David Price sells 150,000 Shares Sep 03 2009 
Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance Dec 11 2008 

More From Other Websites
Nasdaq stocks posting largest volume increases Sep 17 2014
Cornerstone Therapeutics Inc. Stockholders Approve Merger Feb 28 2014
Chiesi Farmaceutici Completes Acquisition of Cornerstone Therapeutics Feb 04 2014
CORNERSTONE THERAPEUTICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Feb 04 2014
Cornerstone Therapeutics Inc. Stockholders Approve Merger Feb 03 2014
CORNERSTONE THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Feb 03 2014
Cornerstone Therapeutics Adjourns Special Meeting of Stockholders Jan 31 2014
Cornerstone Therapeutics Adjourns Special Meeting of Stockholders Jan 31 2014
Cornerstone Therapeutics Launches BETHKIS(R) (Tobramycin Inhalation Solution) for Management of... Nov 20 2013
Cornerstone Therapeutics Launches BETHKIS(R) (Tobramycin Inhalation Solution) for Management of... Nov 20 2013
CORNERSTONE THERAPEUTICS INC Financials Nov 15 2013
Cornerstone Therapeutics Management Discusses Q3 2013 Results - Earnings Call Transcript Nov 07 2013
CORNERSTONE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 07 2013
Cornerstone Therapeutics Reports Third Quarter 2013 Financial Results Nov 07 2013
Cornerstone Therapeutics to Host Third Quarter 2013 Conference Call Oct 31 2013
Cornerstone Therapeutics to Host Third Quarter 2013 Conference Call Oct 31 2013
CORNERSTONE THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Oct 31 2013
Cornerstone Therapeutics Inc. Stockholders Seeking More Money Regarding the Proposed Buyout by... Oct 18 2013
Cornerstone Therapeutics Announces Events to Be Held at the 2013 North American Cystic Fibrosis... Oct 17 2013
Cornerstone Therapeutics Is Selling Itself Too Short Oct 08 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK